Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

In the Spotlight

Healthcare & Life Sciences Market Update

Shiny transparent capsule filled with colorful spheres

September 19, 2024 Podcast

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Close up of Asian women with hi tech digital technology screen over the eye.

May 30, 2024 Webcast

US Regulators’ Joint Inquiry Into Healthcare Consolidation: Navigating the New Landscape

April 30, 2024 Client Alert

US Regulators Announce Inquiry Into Healthcare Consolidation

January 4, 2024 Article

2024 Drug Pricing Look Ahead: Federal, State Drug Pricing Plans Likely to Prompt Challenges

October 30, 2024 Webcast

FDA Life Sciences Enforcement Update: Recent Trends and a Look Ahead

Latham’s Healthcare & Life Sciences practitioners discuss recent trends in FDA enforcement activities and what to expect in the coming year. MCLE credit offered.

October 8, 2024 Client Alert

Middle District of Florida Accepts Justice Thomas’s Invitation: FCA Qui Tam Provision Unconstitutional

The Zafirov decision finds that the False Claims Act qui tam provision violates Article II of the US Constitution.

September 19, 2024 Podcast

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

September 19, 2024 Webcast

The Demise of Chevron Deference and Its Impact on the Healthcare and Life Sciences Industries

September 6, 2024 Client Alert

New FDA Brief in Supreme Court Tobacco Case Puts Spotlight on Post-Chevron Regulatory Landscape

Episode 85 Drug Pricing How Demise Chevron Deference and Other Litigation May Impact Pharma Industry

September 19, 2024

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Recent Supreme Court decisions, such as those overruling Chevron deference, as well as ongoing manufacturer challenges to the Inflation Reduction Act and state 340B laws, will likely have a significant impact on the pharmaceutical industry.

August 19, 2024

Episode 83 — Drug Pricing: How Are Payers Responding to the IRA?

Explore how health insurance companies are adapting to the Inflation Reduction Act's new requirements, including the Part D redesign.

June 21, 2024

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

June 13, 2024

Episode 81 — Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.

May 30, 2024

US Regulators’ Joint Inquiry Into Healthcare Consolidation: Navigating the New Landscape

Latham’s healthcare enforcement and antitrust practitioners discuss how companies can navigate the complexities of healthcare consolidation and regulatory compliance. MCLE credit offered.

March 06, 2024

Next Generation of Nicotine: Center for Tobacco Products — 2024 Outlook

Latham’s FDA Regulatory lawyers discuss CTP’s 2024 agenda for tobacco and nicotine products. MCLE credit offered.

February 21, 2024

2024 FDA Outlook: Healthcare & Life Sciences

Latham’s Healthcare & Life Sciences lawyers discuss FDA’s regulatory and legislative agenda for 2024. MCLE credit offered.

February 01, 2024

Episode 71 — Drug Pricing: A Look Ahead at Trends for 2024

Listen to this “lightning round” to hear how the policy and regulatory environment will likely remain hostile for pharmaceutical manufacturers, and how to address the turbulence that lies ahead.

January 25, 2024

Episode 68 — Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?

A new proposal seeks to reinvigorate the Bayh-Dole Act by allowing government to consider price as a factor when electing to exercise march-in rights.

December 13, 2023

Episode 62 — Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?

New draft guidance document signals an expanded safe harbor for communicating scientific information on unapproved uses of approved medical products.

Episode 61 Drug Pricing New OIG Guidance Reaffirms the Seven Elements of Effective Compliance

December 08, 2023

Episode 61 — Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program

Hear from Latham attorneys and a leading industry practitioner what the OIG compliance guidance means for drug manufacturers.

December 05, 2023

Common Pitfalls in Structuring Non-Dilutive Financings Using Licenses or Collaborations

Latham Healthcare & Life Sciences partners discuss alternative financing through strategic licensing and partnerships as part of the Jefferies London Healthcare Conference.

October 20, 2023